Cohance Lifesciences Ltd

Suven Pharmaceuticals has allotted 12,80,02,184 equity shares of the Company of face value of Re 1 each to the eligible shareholders of Cohance Lifesciences (transferor company) in share exchange ratio of 11:295 in terms of the scheme of amalgamation. Powered by Capital Market - Live

Suven Pharmaceuticals announced that the Ministry of Corporate Affairs, Government of India (MCA), has approved change of name of the Company from 'Suven Pharmaceuticals' to 'Cohance Lifesciences', with effect from 07 May 2025. The change of name has been carried on pursuant to the Scheme of Amalgamation. The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world said Cohance Executive Chairman, Vivek Sharma.Powered by Capital Market - Live

Suven Pharmaceuticals announced that it has received final approval from the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Government of India, for foreign investment under applicable regulations. This marks the final regulatory clearance required to implement the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals, a transaction previously approved by shareholders and sanctioned by the Hon'ble NCLT, Mumbai Bench. In line with the terms of the approved Scheme of Amalgamation, the merger will take effect from the business opening hours of 1st May 2025, following the satisfaction of all prescribed conditions. The merged company will operate under the name Cohance Lifesciences, subject to applicable regulatory approvals, reflecting a unified platform with expanded CDMO capabilities.Powered by Capital Market - Live

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 28 May 2025.Powered by Capital Market - Live

Suven Pharmaceuticals announced that CRISIL has assigned/ reaffirmed the following ratings to the Bank facilities of the Company as under: Long Term Rating - CRISIL A+/Watch Positive (Continues on 'Rating Watch with Positive Implications') Short Term Rating - CRISIL A1+ (Reaffirmed)Powered by Capital Market - Live

Revenue from operations jumped 39.7% to Rs 307.15 crore in Q3 FY25 as compared with Rs 219.82 crore in Q3 FY24. Profit before tax (PBT) stood at Rs 109.73 crore, up 67.6% as compared with Rs 65.47 crore in Q3 FY24. In Q3 FY25, revenue from Suven and Cohance (proforma basis) stood at 6.76 billion, up 40% YoY and Adjusted EBITDA growth of 85% YoY with margins of 38.7% In contract development and manufacturing organization (CDMO) segment, two molecules added this quarter: One molecule advanced to Phase 3 and one directly added to Phase III (laterals addition), increasing total active Phase 3 projects to 15 with 9 molecules. In SpecChem CDMO segment, the company said that it witnessed recovery as expected, following the bottoming out in Q2. On outlook front, the company expects to deliver YoY growth for the combined platform in FY25 on a full year basis, with acceleration expected in FY26. It targets to reach $1 billion revenue, led by an expanding CDMO share, niche tech investments and continued strategic M&A. Vivek Sharma, executive chairman, commented, 'Suven Pharma has reaffirmed its growth trajectory in Q3 FY25 as we had expected. We continue to make BD efforts and remain focused on high-value CDMO offerings and expansion in niche technology platforms in line with our strategic vision. Our investments in ADCs and oligonucleotides with fast underlying market growth position us well for sustained mid and long-term growth. As we gear to deliver our $1 billion revenue guidance with higher CDMO and niche technology share.' V. Prasada Raju, managing director, added: 'We continue to witness a strong momentum in our Pharma CDMO business, with increased RFQ inflows and a robust late-stage pipeline. As our Phase 3 pipeline has expanded now to 15 projects with 9 molecules, gives us comfort on our strategic endeavors moving in the right direction. Our ability to drive innovation with addition of Oligos, deepening our ADC presence, and serve as a trusted partner to global innovators continues to enhance our competitive edge.' Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of the global pharma industry.Powered by Capital Market - Live

Suven Pharmaceuticals Ltd gained 5.19% today to trade at Rs 1099.95. The BSE Healthcare index is up 0.8% to quote at 41147.95. The index is down 4.33 % over last one month. Among the other constituents of the index, NGL Fine Chem Ltd increased 4.34% and Aurobindo Pharma Ltd added 4.1% on the day. The BSE Healthcare index went up 17.3 % over last one year compared to the 6.26% surge in benchmark SENSEX. Suven Pharmaceuticals Ltd has added 4.29% over last one month compared to 4.33% fall in BSE Healthcare index and 0.23% drop in the SENSEX. On the BSE, 2774 shares were traded in the counter so far compared with average daily volumes of 9706 shares in the past one month. The stock hit a record high of Rs 1359 on 02 Dec 2024. The stock hit a 52-week low of Rs 597 on 04 Jun 2024.Powered by Capital Market - Live

Net profit of Suven Pharmaceuticals rose 77.28% to Rs 82.88 crore in the quarter ended December 2024 as against Rs 46.75 crore during the previous quarter ended December 2023. Sales rose 39.73% to Rs 307.15 crore in the quarter ended December 2024 as against Rs 219.82 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales307.15219.82 40 OPM %38.3230.06 - PBDT130.0878.26 66 PBT109.7365.47 68 NP82.8846.75 77 Powered by Capital Market - Live

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc. (target company), at an aggregate consideration of USD 64.4 million, which includes USD 15 million of primary equity infusion into the target company. Powered by Capital Market - Live